-+ 0.00%
-+ 0.00%
-+ 0.00%

Voyager Therapeutics Announces First Peer-Reviewed Publication Of Data Showing Ability Of Alkaline Phosphatase To Transport Novel AAV Capsid Across The Blood-brain Barrier

Benzinga·05/15/2025 11:07:08
Listen to the news

Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV capsid across the blood-brain barrier (BBB). The article, titled "Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier," was published in Molecular Therapy and can be accessed here.